← Back to headlines
Revolution Medicines Updates 2026 Operating Expenses and Prepares for Daraxonrasib Launch
Revolution Medicines has updated its 2026 GAAP operating expense guidance to $2.1 billion-$2.2 billion as it prepares for the potential launch of daraxonrasib.
5 Aug, 23:01 — 5 Aug, 23:01
Sources
Showing 1 of 1 sources
Related Stories
Italy Extends Diesel Fuel Tax Cut Through Early September
17m ago
Cisco Abandons Traditional Hardware Restrictions to Pursue AI Infrastructure Boom
27m ago
Executives at Itron and Lyft Sell Significant Company Stock Holdings
29m ago
Senior Official Firmly Rejects External Political Pressure and Influence Attempts
29m ago